<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925313</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_BEP_101</org_study_id>
    <nct_id>NCT01925313</nct_id>
  </id_info>
  <brief_title>A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers</brief_title>
  <official_title>A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objectives

        -  To compare the safety and pharmacokinetic properties of CJ-30044 and bepotastine
           besylate after a single oral administration in healthy male volunteers.

        -  To evaluate the food-effect on pharmacokinetics of CJ-30044 after a single oral
           administration in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast and Peak plasma concentration (Cmax) of Bepotastine</measure>
    <time_frame>Blood sampling up to 36hs post dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf, Tmax, T1/2 of Bepotastine</measure>
    <time_frame>Blood sampleing up to 36hrs post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CJ-30044</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TALION TAB. 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-30044</intervention_name>
    <description>20.51mg a day,PO,QD</description>
    <arm_group_label>CJ-30044</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TALION TAB. 10mg</intervention_name>
    <description>10mg a day,PO,BID</description>
    <arm_group_label>TALION TAB. 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male volunteers in the age between 20 and 45 years old

               -  BMI(Body Mass Index) in the range of 18.5 to 25kg/m2

          2. Subject with no history of any significant chronic disease

          3. Judged to be in good health on the basis of their vital sign, ECG, physical exam and
             routine laboratory data for this trial by investigators

          4. Willing to adhere to protocol requirements and sign a informed consent form

        Exclusion Criteria:

          1. History of clinically significant allergies, including Bepotastine.

          2. History of clinically significant hepatic, renal, neurology, psychiatric, pulmonary,
             endocrine, hematologic, cardiovascular disease

          3. History of surgery except or gastrointestinal disease which might significantly change
             absorption of medicines

          4. Subjects considered as unsuitable health on the basis of their vital sign, ECG,
             physical exam and routine laboratory data for this trial by investigators.

          5. Clinical laboratory test values are outside the accepted normal range

               -  AST or ALT &gt;1.25 times to normal range

               -  Total bilirubin &gt;1.5 times to normal range

          6. Estimated GFR(Glomerular Filtration Rate) &lt; 80 mL/min/1.73m2

          7. Clinically significant vital sign

               -  SBP(Systolic Blood Pressure) ≤ 90 mmHg or SBP ≥ 150 mmHg

               -  DBP(Diastolic Blood Pressure) ≤ 50 mmHg or DBP ≥ 100 mmHg

          8. History of drug abuse or positive urine screen for drugs

          9. History of caffeine, alcohol, smoking abuse

               -  caffeine &gt; 5 cups/day

               -  alcohol &gt; 210g/week

               -  smoking &gt; 10 cigarettes/day

         10. Special diet known to interfere with the absorption, distribution, metabolism or
             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior
             to drug administration

         11. Use of prescription only medicine and oriental medicine within the 14 days before
             dosing or use of non-prescription medicine within the 7 days before dosing

         12. Participated in a previous clinical trial within 60 days prior to dosing

         13. Donated blood within 60 days prior to dosing

         14. Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Su Park, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei university severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2013</study_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

